31.05.2008 Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate

31.05.2008 Early Data from Apoptosis, Angiogenesis and Growth Regulation Programs Suggest Biologic Activity in a Range of Tumor Types

31.05.2008 Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline

31.05.2008 Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients

31.05.2008Merck KGaA: Erbitux Significantly Prolongs Survival in First-Line Treatment of Non-Small Cell Lung Cancer

31.05.2008 Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women With Advanced HER2-Negative Breast Cancer

30.05.2008 Data from Clinical Trial of MediGene's EndoTAGTM-1 in the Indication Pancreatic Cancer will be presented at ASCO Annual Meeting

30.05.2008 Merck Receives CHMP Positive Opinion for Marketing Authorization for Erbitux Including First-Line Colorectal Cancer in the European Union

27.05.2008 Axis-Shield NycoCard CRP test selected for major study into overuse of antibiotics

27.05.2008 Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

27.05.2008 Avantogen Limited appoints Mr. Pat Elliott as Chairman of the Board of Directors

26.05.2008 NuSep Cancels the Converting Note issue and Announces a Share Purchase Plan

22.05.2008 Amarin announces completion of the first tranche of $60 million private placement. Appoints Four New Directors to Board

22.05.2008 Lundbeck acquires European commercialization rights for Flurizan® from Myriad, USA - a new drug in final phase III development for the treatment of Alzheimer's disease

21.05.2008 Solvay joins Capricorn‘Cleantech’venture capital fund

21.05.2008 Genera Biosystems Limited IPO closes oversubscribed

19.05.2008 Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study

19.05.2008 Bone Medical receives FDA confirmation for clinical trial strategy for osteoporosis product

16.05.2008 Oxford Biomedica Announces TROVAX^® Phase II Trial Results in Renal Cancer to be Presented at ASCO